Business Standard

Friday, December 20, 2024 | 05:11 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pharma Sctors

Online pharmacies suffer without regulatory prescriptions in India

The absence of a legal framework governing this fast-growing segment of the pharma retailing business is causing confusion in the industry

Online pharmacies suffer without regulatory prescriptions in India
Updated On : 02 Mar 2023 | 10:32 PM IST

Indian pharma R&D spends stay stagnant three years after pandemic downturn

Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US

Indian pharma R&D spends stay stagnant three years after pandemic downturn
Updated On : 17 Feb 2023 | 10:40 PM IST

Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady

Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins
Updated On : 18 Jan 2023 | 6:21 PM IST

Pharma firms with India focus preferred as US market concerns grow

Steady outlook and higher returns triggers for companies refining their strategy

Pharma firms with India focus preferred as US market concerns grow
Updated On : 03 Jan 2023 | 10:33 PM IST

BDR Pharma prostate cancer drug at 1/3rd of innovator brand price

The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000

BDR Pharma prostate cancer drug at 1/3rd of innovator brand price
Updated On : 03 Jan 2023 | 7:30 AM IST

Drug regulator halts production at Maiden Pharma's Sonipat unit

Centre forms panel to analyse causal relation between deaths and cough syrups

Drug regulator halts production at Maiden Pharma's Sonipat unit
Updated On : 12 Oct 2022 | 10:13 PM IST

Cash is king! Investing strategies to ride out choppy markets

They turn cautious and prefer defensive bets

Cash is king! Investing strategies to ride out choppy markets
Updated On : 09 Oct 2022 | 10:10 PM IST

Top headlines: Growth forecast, Maiden Pharma cough syrup issue, and more

From World Bank slashing India's economic growth to Maiden Pharma's cough syrup issue, here are the top headlines on Friday morning

Top headlines: Growth forecast, Maiden Pharma cough syrup issue, and more
Updated On : 07 Oct 2022 | 8:41 AM IST

Udaan starts multiple deliveries per day for pharmacies in six cities

Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...

Udaan starts multiple deliveries per day for pharmacies in six cities
Updated On : 29 Sep 2022 | 4:22 PM IST

Land parcels of pharma PSUs find no takers, but momentum likely in few mths

In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process

Land parcels of pharma PSUs find no takers, but momentum likely in few mths
Updated On : 21 Sep 2022 | 11:08 PM IST

Deja vu? Key reasons why Jefferies thinks the market rally may not sustain

The information technology sector (IT), Jefferies believes, remains at significant risk of sell-off if the Nifty were to correct

Deja vu? Key reasons why Jefferies thinks the market rally may not sustain
Updated On : 08 Sep 2022 | 11:59 PM IST

Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore

Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent

Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore
Updated On : 10 Aug 2022 | 11:49 PM IST

Metropolis tanks 27% in 1-mth on promoter stake sale buzz, latter clarifies

The promoters of Metropolis Healthcare on Monday after market hours clarified that they have no intention to exit the business.

Metropolis tanks 27% in 1-mth on promoter stake sale buzz, latter clarifies
Updated On : 14 Jun 2022 | 9:59 AM IST

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos
Updated On : 07 Jun 2022 | 7:19 PM IST

Near-term growth issues and cost pressure could impact Aurobindo Pharma

While valuations are now attractive, product approvals and progress on the injectable guidance are among key long-term term triggers

Near-term growth issues and cost pressure could impact Aurobindo Pharma
Updated On : 03 Jun 2022 | 11:33 PM IST

Paradeep Phosphates IPO gets 29% subscription; retail portion booked 57%

The initial public offer of Paradeep Phosphates was subscribed 29 per cent on the first day of subscription on Tuesday. The IPO received bids for 7,86,87,000 shares against 26,86,76,858 shares on offer, according to data available with NSE. The category for Retail Individual Investors (RIIs) was subscribed 57 per cent and the portion for non-institutional investors attracted 6 per cent subscription. The Initial Public Offer (IPO) has a fresh issue of equity shares aggregating to Rs 1,004 crore and an offer for sale of up to 11,85,07,493 equity shares. As part of the OFS, Zuari Maroc Phosphates Pvt Ltd (ZMPPL) will offload 60,18,493 equity shares and the government of India will sell up to 11,24,89,000 equity shares. The government will be offloading its entire 19.55 per cent stake in the company. Currently, ZMPPL holds 80.45 per cent stake and the government of India owns the rest 19.55 per cent stake in the company. The price range for the offer is at Rs 39-42 per share. On Fr

Paradeep Phosphates IPO gets 29% subscription; retail portion booked 57%
Updated On : 17 May 2022 | 7:45 PM IST

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform

Strong specialty sales and volumes keep it sunny for Sun Pharma
Updated On : 20 Mar 2022 | 8:38 PM IST

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%
Updated On : 16 Feb 2022 | 12:21 AM IST

Ipca Laboratories' PAT declines 26% to Rs 199.9 crore in December quarter

The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing

Ipca Laboratories' PAT declines 26% to Rs 199.9 crore in December quarter
Updated On : 14 Feb 2022 | 8:33 PM IST

Brinton Pharma to launch generic version of anti-Covid pill Molnupiravir

The company will introduce it in the domestic market under the brand 'Molviton'

Brinton Pharma to launch generic version of anti-Covid pill Molnupiravir
Updated On : 30 Dec 2021 | 11:24 PM IST